Fundz
Funding, M&A and exec moves matched to your market, guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

KaliVir Immunotherapeutics secures $14 million in Series A extension financing led by Company K Partners. This funding will support the development of its innovative oncolytic immunotherapy programs.

PRIVATEAug 19, 2026•about 5 hours ago

Amount Raised

$14 Million

Round Type

Series A

Pittsburgh

Investors

Quad Investment ManagementNextransFlexus PartnersSv InvestmentCompany K Partners

Description

KaliVir Immunotherapeutics, Inc. has closed a $14 million extension of its Series A financing. The financing was led by Company K Partners, with participation from SV Investment, Flexus Partners, and existing investors. This round will further support the company's clinical-stage projects

Company Information

Company

KaliVir Immunotherapeutics

Location

Pittsburgh, Pennsylvania, United States

About

KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, next-generation oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread (Vaccinia Enhanced Template "VET" Platform). VET Platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients' immune systems and modify the tumor microenvironment. KaliVir's oncolytic product candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir and Astellas Pharma are developing KaliVir's VET2-L2 oncolytic virus for immuno-oncology through a worldwide licensing agreement. Simultaneously, KaliVir is in the process of advancing multiple therapeutic candidates toward the clinic. For more information, please visit www.kalivir.com.

Don't miss KaliVir Immunotherapeutics's next move

Get an email the moment KaliVir Immunotherapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for KaliVir Immunotherapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

KaliVir Immunotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.